Medical - Devices
Compare Stocks
2 / 10Stock Comparison
DCTH vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
DCTH vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $399M | $159.85B |
| Revenue (TTM) | $65M | $10.58B |
| Net Income (TTM) | $561K | $2.98B |
| Gross Margin | 118.8% | 66.3% |
| Operating Margin | -2.5% | 30.5% |
| Forward P/E | 169.8x | 43.3x |
| Total Debt | $936K | $303M |
| Cash & Equiv. | $43M | $3.37B |
DCTH vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Delcath Systems, In… (DCTH) | 100 | 147.0 | +47.0% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DCTH vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DCTH is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 129.1%, EPS growth 107.3%, 3Y rev CAGR 215.3%
- Lower volatility, beta 1.65, Low D/E 0.8%, current ratio 10.92x
- 129.1% revenue growth vs ISRG's 20.5%
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.00
- 5.5% 10Y total return vs DCTH's -98.8%
- Beta 1.00, current ratio 4.87x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 129.1% revenue growth vs ISRG's 20.5% | |
| Value | Lower P/E (43.3x vs 169.8x) | |
| Quality / Margins | 28.2% margin vs DCTH's 0.9% | |
| Stability / Safety | Beta 1.00 vs DCTH's 1.65 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -16.4% vs DCTH's -20.1% | |
| Efficiency (ROA) | 14.8% ROA vs DCTH's 0.5%, ROIC 15.0% vs 0.9% |
DCTH vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DCTH vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 161.7x DCTH's $65M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to DCTH's 0.9%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $65M | $10.6B |
| EBITDAEarnings before interest/tax | -$1M | $3.8B |
| Net IncomeAfter-tax profit | $561,000 | $3.0B |
| Free Cash FlowCash after capex | $19M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +118.8% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -2.5% | +30.5% |
| Net MarginNet income ÷ Revenue | +0.9% | +28.2% |
| FCF MarginFCF ÷ Revenue | +29.3% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.1% | +18.8% |
Valuation Metrics
DCTH leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 57.2x trailing earnings, ISRG trades at a 66% valuation discount to DCTH's 169.8x P/E. On an enterprise value basis, ISRG's 43.3x EV/EBITDA is more attractive than DCTH's 353.2x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $399M | $159.8B |
| Enterprise ValueMkt cap + debt − cash | $356M | $156.8B |
| Trailing P/EPrice ÷ TTM EPS | 169.82x | 57.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.35x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.63x |
| EV / EBITDAEnterprise value multiple | 353.19x | 43.28x |
| Price / SalesMarket cap ÷ Revenue | 4.68x | 15.88x |
| Price / BookPrice ÷ Book value/share | 4.12x | 9.10x |
| Price / FCFMarket cap ÷ FCF | 19.02x | 64.18x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $1 for DCTH. DCTH carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ISRG's 0.02x. On the Piotroski fundamental quality scale (0–9), DCTH scores 7/9 vs ISRG's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +0.5% | +16.9% |
| ROA (TTM)Return on assets | +0.5% | +14.8% |
| ROICReturn on invested capital | +0.9% | +15.0% |
| ROCEReturn on capital employed | +0.7% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 0.02x |
| Net DebtTotal debt minus cash | -$43M | -$3.1B |
| Cash & Equiv.Liquid assets | $43M | $3.4B |
| Total DebtShort + long-term debt | $936,000 | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
Evenly matched — DCTH and ISRG each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $11,189 for DCTH. Over the past 12 months, ISRG leads with a -16.4% total return vs DCTH's -20.1%. The 3-year compound annual growth rate (CAGR) favors DCTH at 23.5% vs ISRG's 14.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +15.4% | -19.9% |
| 1-Year ReturnPast 12 months | -20.1% | -16.4% |
| 3-Year ReturnCumulative with dividends | +88.2% | +48.5% |
| 5-Year ReturnCumulative with dividends | +11.9% | +61.7% |
| 10-Year ReturnCumulative with dividends | -98.8% | +549.2% |
| CAGR (3Y)Annualised 3-year return | +23.5% | +14.1% |
Risk & Volatility
ISRG leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than DCTH's 1.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 74.5% from its 52-week high vs DCTH's 63.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.65x | 1.00x |
| 52-Week HighHighest price in past year | $18.23 | $603.88 |
| 52-Week LowLowest price in past year | $8.12 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +63.0% | +74.5% |
| RSI (14)Momentum oscillator 0–100 | 61.2 | 43.6 |
| Avg Volume (50D)Average daily shares traded | 354K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DCTH as "Buy" and ISRG as "Buy". Consensus price targets imply 100.3% upside for DCTH (target: $23) vs 38.3% for ISRG (target: $623).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $23.00 | $622.60 |
| # AnalystsCovering analysts | 11 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.5% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DCTH leads in 1 (Valuation Metrics). 1 tied.
DCTH vs ISRG: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is DCTH or ISRG a better buy right now?
For growth investors, Delcath Systems, Inc.
(DCTH) is the stronger pick with 129. 1% revenue growth year-over-year, versus 20. 5% for Intuitive Surgical, Inc. (ISRG). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 2x trailing P/E (43. 3x forward), making it the more compelling value choice. Analysts rate Delcath Systems, Inc. (DCTH) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DCTH or ISRG?
On trailing P/E, Intuitive Surgical, Inc.
(ISRG) is the cheapest at 57. 2x versus Delcath Systems, Inc. at 169. 8x.
03Which is the better long-term investment — DCTH or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +61. 7%, compared to +11. 9% for Delcath Systems, Inc. (DCTH). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus DCTH's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DCTH or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 00β versus Delcath Systems, Inc. 's 1. 65β — meaning DCTH is approximately 65% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Delcath Systems, Inc. (DCTH) carries a lower debt/equity ratio of 1% versus 2% for Intuitive Surgical, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DCTH or ISRG?
By revenue growth (latest reported year), Delcath Systems, Inc.
(DCTH) is pulling ahead at 129. 1% versus 20. 5% for Intuitive Surgical, Inc. (ISRG). On earnings-per-share growth, the picture is similar: Delcath Systems, Inc. grew EPS 107. 3% year-over-year, compared to 22. 6% for Intuitive Surgical, Inc.. Over a 3-year CAGR, DCTH leads at 215. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DCTH or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 3. 2% for Delcath Systems, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 0. 8% for DCTH. At the gross margin level — before operating expenses — DCTH leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DCTH or ISRG more undervalued right now?
Analyst consensus price targets imply the most upside for DCTH: 100.
3% to $23. 00.
08Which pays a better dividend — DCTH or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is DCTH or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +549. 2% 10Y return). Delcath Systems, Inc. (DCTH) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +549. 2%, DCTH: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DCTH and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.